What type of stem cells are used for degenerative disc disease?

We use mesenchymal stem cells (MSCs). These may come from: Autologous sources — the patient’s own bone marrow or adipose (fat) tissue. Allogeneic sources — ethically donated, carefully screened umbilical cord MSCs. Each approach has different characteristics, and the selection depends on clinical factors, medical history, and the treatment plan designed for each patient.

How do I know if I’m a good candidate for stem cell therapy for disc degeneration?

You may be a candidate if you have: Disc degeneration confirmed by MRI Chronic low back pain that has not improved with conservative treatments No active infection or uncontrolled chronic illness Adequate disc structure, since cases with severe collapse or advanced structural damage may have limited potential for benefit. Eligibility can be assessed through a detailed review of your imaging, symptoms, and medical history before you travel.

As with any medical procedure, there are potential risks. These vary depending on the type of stem cells used, the injection technique, and each patient’s individual health profile. Reported risks may include: Temporary soreness or swelling at the injection site Mild inflammation or discomfort at the treated area Rare risk of infection Rare reaction to local anesthesia Your physician will review all potential risks and safety considerations with you so that you can make an informed decision.

Stem Cell Therapy for Degenerative Disc Disease (DDD) & Back Pain

At the Stem Cells Transplant Institute, we offer stem cell therapy for degenerative disc disease and back pain to help reduce inflammation, support spinal health, improve mobility, and promote the body’s natural healing processes.

Reviewed: 19 Apr 2026

What Is Degenerative Disc Disease (DDD)?

DDD refers to the gradual loss of hydration, height, or structural integrity of the spinal discs. These changes can contribute to pain, nerve irritation, or reduced mobility.

Spinal discs act as shock absorbers between the vertebrae. With aging or after injury, discs can deteriorate. Each disc has two main components: a firm outer layer and a soft, jelly-like core. Loss of hydration in the inner core decreases its ability to absorb shock and may reduce disc height, narrowing the space between vertebrae. Damage or weakening of the outer layer can lead to small cracks or tears that may allow the inner material to protrude or leak.

These changes may contribute to chronic low back pain and, in some cases, radiating pain into the legs if nearby nerves become compressed.

According to the Global Burden of Disease Study (2021), more than 619 million people worldwide live with low back pain, making it the leading cause of disability across all age groups. Degenerative disc disease is one of the most common contributors, increasingly affecting adults as they age.

Why Seek Stem Cell Therapy for Degenerative Disc Disease in Costa Rica?

Chronic back pain from degenerative disc disease (DDD) affects how people work, sleep, and move through daily life — and for patients who have not found adequate relief through conservative management, Stem Cells Transplant Institute in Costa Rica offers a physician-supervised MSC alternative therapy.

Costa Rica attracts patients from the United States, Canada, and Europe seeking a regenerative approach administered and supervised by physicians at a reasonable cost.

At Stem Cell Transplant Institute, imaging studies are reviewed before any travel is scheduled, our protocols are built around each patient’s specific spinal anatomy, and most programs are completed within two to four days.

MRI or CT review, pain pattern history, and prior treatment records are part of the intake process for every DDD patient. The protocol is designed around the specific disc damage levels involved and the patient’s current functional limitations..

Common Characteristics

Chronic low back pain
Nerve-related radiating pain (sciatica)
Stiffness and reduced tolerance for bending, lifting, or prolonged sitting.
Numbness or weakness in the arms or legs when nerves are affected

Evidence-Based Treatment

Why Stem Cell Therapy for DDD?

Conventional treatments such as physical therapy, medications, and targeted injections may help reduce symptoms but often provide temporary or partial relief. Surgery may offer long-term benefit in selected cases, but it can involve significant recovery time and may not be appropriate for everyone.

Research in regenerative medicine suggests that mesenchymal stem cells may support disc health by helping modulate inflammation, promoting a more favorable microenvironment, and supporting the survival and function of disc cells. These effects may contribute to improvements in pain, mobility, and overall function in some patients, and in certain cases may help delay the need for more invasive procedures.

Soothing inflammation

Mesenchymal stem cells (MSCs) naturally release anti-inflammatory mediators that may help calm the chronic inflammation associated with disc degeneration and back pain. These signals can reduce inflammatory activity around discs and nearby nerves. (Noriega et al., 2017)

Supporting disc cells

MSCs may help support cells inside the disc (called nucleus pulposus and annulus fibrosus cells) by improving their ability to withstand stress and maintain extracellular matrix components. Research indicates that MSCs can promote healthier disc-cell activity, which may help preserve disc structure. (Richardson et al., 2017)

Improving local tissue health

MSCs secrete growth factors that support natural repair processes. These signals may stimulate resident disc cells, promote extracellular matrix production, and support disc hydration. (Orozco et al., 2011)

Enhancing the spinal micro-environment

MSCs may help improve nutrient exchange, modulate immune responses, and support a more balanced microenvironment within surrounding tissues. These effects may contribute to better functional stability. (Sakai et al., 2018)

Potential pain-modulating effects

MSCs may help modulate pain pathways by reducing inflammation around nerve roots and altering inflammatory signaling involved in pain perception. (Xu et al., 2020)

Expected Benefits and Clinical Observations

Although individual responses vary widely, published studies and clinical observations have reported potential supportive improvement in the following functional domains:

Reduced pain

25-45%

Improved function

15-40%

Reduced nerve-related symptoms

10-35%

*These percentages summarizes ranges reported in selected clinical studies and observational cohorts under controlled conditions and standardized outcomes measures. They are not specific to any single study or to treatments performed at Stem Cells Transplant Institute. They should not be interpreted as averages, promises, or guaranteed results for individual patients. Evidence for MSC therapy in degenerative disc disease remains preliminary, and ongoing controlled clinical trials are still evaluating the magnitude, durability and consistency of these effects. All observations should be considered exploratory and hypothesis-generating rather than definitive proof of efficacy.

Timeline of Reported Improvements

Published studies and patient-reported outcomes suggest that improvements after mesenchymal stem cell (MSC) therapy for degenerative disc disease may develop gradually over time. These timelines are illustrative summaries rather than predictions, and individual responses vary significantly.

1-3 months

Some studies report early reduction in sharp or activity-related pain, as well as improved tolerance for standing or walking.

3-6 months

Several reports describe progressive improvement in daily function, mobility, and deecreased reliance on pain medication

6-12 months

Some reports show maintained or continued functional gains and greater stability in movement patterns.

*These timelines summarize patterns reported across selected published studies and observational cohorts. They are not specific predictions, and they do not represent expected outcomes for any individual patient. Individual experiences vary considerably, and some patients may experience minimal or no improvement. Evidence for MSC therapy in degenerative disc disease remains preliminary, and larger controlled clinical trials are needed to validate these observations. All timelines should be interpreted as exploratory and non-confirmatory.

Patient Stories & Testimonials

Frequently Asked Questions

Most patients experience recovery within a short period of time, although individual responses vary. Light activity is usually possible the same or next day, and it is common to feel temporary soreness or discomfort in the treated area for a few days.

Improvements typically develop gradually. Some patients report early changes within the first 1–2 months, while others notice more meaningful improvement around 3–6 months as the biological effects of the cells evolve over time. Because each case is different, no specific timeline can be predicted for any individual patient.

We use mesenchymal stem cells (MSCs). These may come from:

Autologous sources — the patient’s own bone marrow or adipose (fat) tissue.
Allogeneic sources — ethically donated, carefully screened umbilical cord MSCs.

Each approach has different characteristics, and the selection depends on clinical factors, medical history, and the treatment plan designed for each patient.

Yes. Stem cell therapy is often incorporated as part of a broader care plan. Physical therapy, core-strengthening exercises, targeted rehabilitation, pain-management strategies, and anti-inflammatory lifestyle changes can complement the treatment.

We will help you determine which therapies pair safely and effectively with your stem cell treatment and the appropriate timing for introducing them.

You may be a candidate if you have:

Disc degeneration confirmed by MRI
Chronic low back pain that has not improved with conservative treatments
No active infection or uncontrolled chronic illness
Adequate disc structure, since cases with severe collapse or advanced structural damage may have limited potential for benefit.

Eligibility can be assessed through a detailed review of your imaging, symptoms, and medical history before you travel.

Yes. We offer virtual consultations to review your MRI, medical history, current symptoms, medications, and treatment goals before you decide to travel. This helps determine whether stem cells therapy may be appropriate for your condition and gives you the opportunity to ask questions, and understand the next steps.

At Stem Cell Transplant Institute, a typical treatment process will likely include an initial evaluation ( in person or virtual), imaging review (MRI, CT, X-ray), the creation of a personalized treatment plan, stem cell collection or preparation (depending on the type of cells used), cell administration typically performed by a spine specialist using image guidance when appropriate, and post- treatment monitoring and follow up.

Most patients can return to their hotel the same day, although temporary soreness in the treated area can occur.

As with any medical procedure, there are potential risks. These vary depending on the type of stem cells used, the injection technique, and each patient’s individual health profile. Reported risks may include:

Temporary soreness or swelling at the injection site
Mild inflammation or discomfort at the treated area
Rare risk of infection
Rare reaction to local anesthesia

Your physician will review all potential risks and safety considerations with you so that you can make an informed decision.

Current research suggests that MSCs may help support disc health by reducing inflammation, improving the disc environment, and supporting the activity of existing disc cells. However, they cannot fully restore a disc to its original structure or reverse advanced degeneration.

The primary goals of MSCs therapy are to support comfort, mobility, and quality of life—not complete disc regeneration.

Mesenchymal Stem Cell Therapy for Degenerative Disc Disease

Stem Cells International • 2021

Systematic review and meta-analysis of randomized controlled trials evaluating safety and clinical efficacy of mesenchymal stem cell therapy for degenerative disc disease.

Stem Cell Therapy for Intervertebral Disc Degeneration

World Journal of Stem Cells • 2025

Scientific review describing recent clinical progress in stem cell therapy, including exosome-based and gene vector strategies for disc degeneration.

Regenerative Medicine in Spine Care Using Mesenchymal Stem Cells

Journal of Stem Cell Research • 2025

Clinical review discussing therapeutic potential of mesenchymal stem cells for chronic low back pain and spinal degenerative conditions.

info

Location

San José, Costa Rica

info@stemcellstransplantinstitute.com

Call Center

+1 888 785-4170

APPLY TODAY